Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Onycholysis associated with paclitaxel.

Julian Mackay-Wiggan1, Kesav G Nair, Charles L G Halasz

  • 1Department of Dermatology, Columbia University-New York Presbyterian Hospital, New York, USA.

Cutis
|March 29, 2003
PubMed
Summary

Paclitaxel chemotherapy can cause nail loss and onycholysis, a condition where nails separate from the nail bed. Dermatologists should recognize this side effect to avoid unnecessary treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.

Journal of the American Academy of Dermatology·2021
Same author

An open-label study evaluating the efficacy of abatacept in alopecia areata.

Journal of the American Academy of Dermatology·2020
Same author

Transient eruptive keratoacanthomas associated with nivolumab.

JAAD case reports·2019
Same author

High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.

JCI insight·2018
Same author

Alopecia areata is a medical disease.

Journal of the American Academy of Dermatology·2018
Same author

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

JCI insight·2016

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Chemotherapeutic agents frequently cause cutaneous side effects.
  • Paclitaxel is a commonly used taxoid chemotherapy drug.
  • Few dermatologic adverse effects have been reported for paclitaxel compared to docetaxel.

Observation:

  • A patient undergoing paclitaxel treatment for lung cancer developed onycholysis and nail loss.
  • This specific adverse dermatologic event associated with paclitaxel has not been widely reported in American literature.

Findings:

  • Paclitaxel use can lead to onycholysis and nail loss.
  • This finding has been previously associated with docetaxel but is less documented for paclitaxel.

Implications:

  • Dermatologists must be aware of onycholysis as a potential side effect of paclitaxel.
  • Early recognition can prevent misdiagnosis and unnecessary treatments like antibiotics or antifungals.
  • Nail regrowth is expected after paclitaxel therapy completion; drug discontinuation is usually not required.

Related Experiment Videos